Lyka Labs

Why is Lyka Labs Ltd falling/rising?

As of 26-Aug, Lyka Labs Ltd's stock price is rising to 74.40, up 1.32%. This increase is driven by strong performance compared to the Sensex, significant growth over the past month, and heightened investor interest.

As of 26-Aug, Lyka Labs Ltd's stock price is rising, currently at 74.40, reflecting an increase of 0.97 (1.32%). This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 5.37% compared to the Sensex's 0.73%. Additionally, the stock has shown significant growth over the past month, with a 17.04% increase, while the Sensex only rose by 1.86%. <BR><BR>Today's performance indicates that Lyka Labs is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is a positive sign for investors. Furthermore, there has been a notable increase in investor participation, with delivery volume on 25 August rising by 1415.11% against the 5-day average, suggesting heightened interest in the stock. <BR><BR>Overall, these factors contribute to the rising stock price of Lyka Labs Ltd.

Which are the latest news on Lyka Labs?

Should I buy, sell or hold Lyka Labs Ltd?

Who are in the management team of Lyka Labs?

The management team of Lyka Labs includes Kunal Narendra Gandhi (Chairman, Managing Director, and CEO), Sandeep P Parikh (Non-Executive Independent Director), Yogesh B Shah (CFO), Dhara P. Shah (Non-Executive Independent Director), Kishore P Shah (Company Secretary), Babulal Jain (Independent Director), Prashant Godha (Director), and Shashil Mendonsa (Director). They are responsible for the company's strategic direction and operations.

The management team of Lyka Labs includes the following key individuals:<BR><BR>1. **Kunal Narendra Gandhi** - Chairman, Managing Director, and CEO<BR>2. **Sandeep P Parikh** - Non-Executive and Independent Director<BR>3. **Yogesh B Shah** - Executive Director and Chief Financial Officer<BR>4. **Dhara P. Shah** - Non-Executive and Independent Director<BR>5. **Kishore P Shah** - Company Secretary and Compliance Officer<BR>6. **Babulal Jain** - Independent Director<BR>7. **Prashant Godha** - Director<BR>8. **Shashil Mendonsa** - Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

What does Lyka Labs do?

Lyka Labs Ltd is a micro-cap company in the pharmaceuticals and biotechnology sector, focusing on healthcare products, including ayurvedic and animal health care. As of June 2026, it reported net sales of 42 Cr and a net profit of 2 Cr.

Overview: <BR>Lyka Labs Ltd is a company engaged in the pharmaceuticals and biotechnology industry, operating within the micro-cap market segment.<BR><BR>History: <BR>Lyka Labs Ltd was incorporated in 1983, initially focusing on manufacturing formulations. It expanded its operations by merging with Lyphin Chemicals Pvt Ltd in April 1983 and has since diversified into various healthcare products, including ayurvedic and animal health care products. The latest quarterly results reported net sales and profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 42 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 242 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.51 <BR>Return on Equity: -10.87% <BR>Price to Book: 2.62<BR><BR>Contact Details: <BR>Address: 4801/B & 4802/A, GIDC Industrial Estate Ankleshwar Gujarat : 393002 <BR>Tel: 91-02646-221422/220549 <BR>Email: companysecretary@lykalabs.com <BR>Website: http://www.lykalabs.com

Who are the peers of the Lyka Labs?

Lyka Labs' peers include Everest Organics, Astonea Labs, Zenotech Lab, Aarey Drugs, Oxygenta Pharma, Sanjiv.Parant, Gennex Lab, Nectar Lifesci, and Accretion Pha. Lyka Labs has average management risk, below average growth, and the lowest 1-year return at -34.01% compared to its peers.

Peers: The peers of Lyka Labs are Everest Organics, Astonea Labs, Zenotech Lab., Aarey Drugs, Oxygenta Pharma, Sanjiv.Parant., Gennex Lab., Nectar Lifesci., and Accretion Pha.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Accretion Pha., while Average management risk is found at Everest Organics, Astonea Labs, Zenotech Lab., Gennex Lab., Nectar Lifesci., and Lyka Labs, and the rest. Below Average management risk is noted at Aarey Drugs. In terms of Growth, Excellent growth is seen at Accretion Pha. and Good growth at Astonea Labs, Sanjiv.Parant., and Gennex Lab., while Below Average growth is present at Everest Organics, Zenotech Lab., Aarey Drugs, Lyka Labs, and Nectar Lifesci., and the rest. Capital Structure is Excellent at Zenotech Lab. and Gennex Lab., Below Average at Everest Organics, Astonea Labs, Aarey Drugs, Lyka Labs, and Nectar Lifesci., and the rest.<BR><BR>Return Snapshot: Astonea Labs has the highest 1-year return at 62.76%, while Lyka Labs has the lowest at -34.01%. Compared to its peers, Lyka Labs' return is significantly lower. Additionally, the six-month return is negative for Everest Organics, Zenotech Lab., Gennex Lab., and Nectar Lifesci.

How big is Lyka Labs?

As of 14th August, Lyka Labs Ltd has a market capitalization of 242.22 Cr and reported Net Sales of 137.73 Cr, with a Net Profit loss of 8.90 Cr over the latest four quarters. Shareholder's Funds are valued at 92.39 Cr, and Total Assets amount to 174.54 Cr as of March 2026.

As of 14th August, Lyka Labs Ltd has a market capitalization of 242.22 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Lyka Labs reported Net Sales of 137.73 Cr. However, the company experienced a loss of 8.90 Cr in Net Profit during the same period.<BR><BR>The latest reporting period for the balance sheet is March 2026. Shareholder's Funds are valued at 92.39 Cr, while Total Assets amount to 174.54 Cr.

When is the next results date for Lyka Labs Ltd?

The next results date for Lyka Labs Ltd is 10 August 2026.

The next results date for Lyka Labs Ltd is scheduled for 10 August 2026.

Are Lyka Labs Ltd latest results good or bad?

Lyka Labs Ltd's latest Q4 FY26 results are concerning, showing a net loss of ₹7.61 crores and a 16.15% revenue decline, marking the lowest quarterly revenue in seven quarters. Analysts have downgraded the company's financial outlook to "Negative," indicating significant operational challenges and a bleak future without a turnaround strategy.

Lyka Labs Ltd's latest results for Q4 FY26 are concerning and indicate a significant deterioration in financial performance. The company reported a net loss of ₹7.61 crores, which marks a drastic decline of 529.94% year-on-year. Revenue also fell to ₹28.03 crores, down 16.15% compared to the same quarter last year and representing the lowest quarterly revenue in the past seven quarters.<BR><BR>The operating margin has turned deeply negative at -23.05%, the worst level recorded, and the profit after tax (PAT) margin is at -28.79%, highlighting severe operational inefficiencies. The company's financial trend has been downgraded to "Negative" by analysts, reflecting growing concerns about its operational viability.<BR><BR>Additionally, the stock has underperformed significantly, declining 47.08% over the past year, which is starkly worse than both the Sensex and the pharmaceuticals sector. Overall, these results suggest that Lyka Labs is facing a critical operational crisis, and the outlook appears bleak without a clear turnaround strategy.

Is Lyka Labs overvalued or undervalued?

As of November 13, 2025, Lyka Labs is considered overvalued with a high PE ratio of 156.53 and a significant decline in performance, contrasting with its peers, which have more attractive valuations and growth expectations.

As of 13 November 2025, Lyka Labs has moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company is currently considered overvalued based on its high PE ratio of 156.53, an EV to EBIT of 119.79, and a Price to Book Value of 3.16. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Lyka Labs' PE ratio significantly exceeds that of Cipla, which stands at 22.65, and Dr. Reddy's Labs at 17.86, both of which are classified as attractive. Additionally, while Lyka Labs has a PEG ratio of 0.00, indicating no growth expectations, its peers like Sun Pharma and Divi's Lab are categorized as expensive with PEG ratios of 11.96 and 1.99, respectively. The recent performance of Lyka Labs shows a substantial decline, with a year-to-date return of -43.61%, contrasting sharply with the Sensex's positive return of 8.11% during the same period, further reinforcing the overvaluation narrative.

How has been the historical performance of Lyka Labs?

Lyka Labs has shown fluctuating historical performance, with net sales increasing from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, while total operating income peaked at 194.08 Cr in Mar'22 before declining. Despite rising costs and low cash flow, the company improved profitability, achieving a profit after tax of 7.93 Cr in Mar'25, recovering from previous losses.

Answer:<BR>The historical performance of Lyka Labs shows a fluctuating trajectory over the years, with notable improvements in recent periods.<BR><BR>Breakdown:<BR>Lyka Labs' net sales increased from 93.07 Cr in Mar'23 to 138.50 Cr in Mar'25, reflecting a positive growth trend. However, the total operating income peaked at 194.08 Cr in Mar'22 before declining to 138.50 Cr in Mar'25. The total expenditure, excluding depreciation, rose from 76.23 Cr in Mar'23 to 120.56 Cr in Mar'25, indicating rising costs. Operating profit (PBDIT) showed volatility, with a high of 103.24 Cr in Mar'22, dropping to 20.17 Cr in Mar'25. Profit before tax improved to 11.12 Cr in Mar'25 from a loss of 13.23 Cr in Mar'23, while profit after tax also turned positive at 7.93 Cr in Mar'25, recovering from losses in previous years. The company's total assets increased to 176.21 Cr in Mar'25, up from 151.52 Cr in Mar'23, and total liabilities also rose to 176.21 Cr in Mar'25. Cash flow from operating activities remained low at 1.00 Cr in Mar'25, with a net cash outflow of 4.00 Cr. Overall, while Lyka Labs has shown signs of recovery in profitability and sales, it continues to face challenges with rising costs and cash flow management.

What is the technical trend for Lyka Labs?

As of June 2, 2025, Lyka Labs shows a mildly bearish trend, supported by daily moving averages and a bearish monthly MACD, despite mixed signals from the weekly MACD and Bollinger Bands.

As of 2 June 2025, the technical trend for Lyka Labs has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD is mildly bearish, indicating mixed signals. The daily moving averages are also mildly bearish, reinforcing the bearish sentiment. Bollinger Bands on the monthly chart show a bearish trend, while both the KST and Dow Theory indicate no clear trend on a monthly basis. Overall, the current stance is mildly bearish, with the daily moving averages and monthly MACD being key indicators driving this outlook.

Who are the top shareholders of the Lyka Labs?

The top shareholders of Lyka Labs primarily include promoters, with Ipca Laboratories Limited as the largest shareholder at 40.98%. Other notable shareholders are Thermo Capital Private Limited (1.55%) and individual investors (31.18%), along with minimal stakes from mutual funds and foreign institutional investors.

The top shareholders of Lyka Labs include several key players. The majority of the shares are held by promoters, with Ipca Laboratories Limited being the largest individual shareholder, holding 40.98%. Other notable shareholders include Thermo Capital Private Limited, which holds 1.55%, and individual investors collectively owning 31.18%. Additionally, there are four mutual fund schemes with a very small stake of 0.01% and five foreign institutional investors (FIIs) holding 0.23%. Overall, the promoter group plays a significant role in the ownership structure of Lyka Labs.

Has Lyka Labs declared dividend?

No Dividend History Available